GLP-1 Medications and Metabolic Health

HormoneSynergy® | Evidence-Based Preventive Longevity Medicine
Portland–Lake Oswego, Oregon
Updated October 2026

GLP-1-based medications have expanded the options available to people whose weight and metabolic health have been difficult to improve with previous treatment. For appropriately selected patients, semaglutide and tirzepatide can reduce appetite, support substantial fat loss and improve blood glucose regulation. Their clinical value becomes clearer when those changes are considered alongside cardiovascular risk, physical function and the ability to maintain adequate nutrition during treatment.

At HormoneSynergy®, weight management is part of comprehensive preventive longevity care. We assess how treatment affects fat distribution, lean tissue, strength, energy and relevant metabolic findings over time. This is particularly important for adults entering later decades of life, when reducing excess fat and preserving physical capability need to be addressed together.

What Are GLP-1-Based Medications?

GLP-1 is a hormone involved in the body’s response to food. Medications acting on this pathway can increase satiety, reduce appetite, slow gastric emptying and improve glucose-dependent insulin secretion. Semaglutide is a GLP-1 receptor agonist. Tirzepatide combines activity at the GLP-1 receptor with activity at the glucose-dependent insulinotropic polypeptide, or GIP, receptor.

Although these medications are often discussed together, their formulations, doses and approved indications differ. Prescribing requires a review of the person’s diagnosis, weight-related complications, medications and medical history. Insulin resistance or an interest in longevity alone does not establish that a medication is appropriate.

Why They Matter in Preventive Longevity Medicine

Excess visceral fat is associated with insulin resistance and other cardiometabolic concerns. Reducing it can be a meaningful treatment goal, particularly when elevated glucose, blood pressure, abnormal lipids or weight-related limitations are already present. GLP-1-based therapy can help selected patients achieve changes that have been difficult to sustain through previous approaches.

The relevance to longevity medicine comes from treating established health risks and preserving function. Weight loss should be interpreted alongside blood pressure, glucose control, lipid management, fitness and the person’s ability to remain active. These medications can contribute to that strategy, but treatment should be selected for a clinical indication rather than presented as a general prescription for extending lifespan.

What Body-Composition Studies Tell Us

The DEXA substudy of the SURMOUNT-1 trial found that approximately 75% of the weight lost with tirzepatide was fat mass and 25% was lean mass. Similar proportions were observed in the placebo group, although total weight loss was substantially greater with tirzepatide. An exploratory STEP-1 analysis of semaglutide also found reductions in fat and visceral fat alongside a reduction in total lean mass.

These findings support attention to lean tissue during treatment, but they should not be interpreted as proof that a fixed percentage of every patient’s weight loss will be muscle. DEXA lean mass includes water and other nonfat, nonbone tissues as well as muscle. A person’s age, baseline body composition, activity, nutrition and amount of weight lost can influence the result.

Clinically, the concern is whether weight loss is accompanied by declining strength, reduced activity or difficulty meeting nutritional needs. Tracking these changes provides more useful guidance than interpreting scale weight in isolation. An improving lean-mass percentage can coexist with a decrease in the absolute amount of lean tissue, which is another reason to review the full report.

Nutrition When Appetite Falls

The 2025 joint clinical advisory from leading nutrition, obesity and lifestyle-medicine organizations emphasizes nutrient adequacy during GLP-1 therapy. When appetite falls, smaller meals still need to supply sufficient protein, fiber, vitamins, minerals and fluid. A protein-conscious, plant-forward Mediterranean eating pattern can be adapted to appetite and tolerance, using foods such as fish, eggs, yogurt, tofu, legumes, vegetables, fruit and whole grains.

Protein targets of approximately 1.2–1.6 grams per kilogram per day have been proposed during weight reduction. This is a planning range, not a universal prescription; the appropriate weight basis, kidney function, activity and nutritional status require consideration. Including protein across meals may make the target easier to reach, with a supplement useful when food intake remains inadequate.

Smaller portions and slower eating can help with tolerance. Fiber should be increased gradually, and hydration individualized, particularly when constipation, vomiting or diarrhea occurs. Persistent difficulty eating or drinking warrants a treatment review. Supplements are selected for identified needs rather than added automatically because someone uses a GLP-1 medication.

Our What Vitamins Should I Take? guide provides additional context for nutritional assessment, testing and supplement safety.

Preserving Muscle and Physical Function

Resistance training provides the stimulus that encourages the body to maintain strength during weight loss. Adequate protein supports that process, but increasing protein without challenging the muscles does not provide the same training signal. A practical program should address the major muscle groups and progress according to the person’s experience, physical limitations and recovery.

For many adults, two or three resistance sessions each week offer a workable starting structure. Machines, free weights, resistance bands and appropriately selected body-weight exercises can all be used. Walking and other aerobic activity support endurance and cardiovascular health, while balance work may be especially relevant for older adults or anyone with a history of falls.

The strongest rationale for this approach comes from the broader evidence on resistance exercise and nutrition during aging and weight reduction. Research continues to refine how best to preserve muscle specifically during semaglutide and tirzepatide treatment. In practice, declining strength or exercise tolerance should prompt reassessment of intake, training, weight-loss pace and other medical contributors.

Using DEXA and SECA to Guide Follow-Up

DEXA body-composition testing estimates fat mass, lean tissue, regional distribution and visceral fat. Bone density requires the appropriate skeletal measurements and remains a separate consideration within the assessment. A baseline scan can help establish the starting point, with repeat testing selected when it is likely to influence care.

SECA body-composition analysis can provide additional trend information between scans. Because bioimpedance estimates are affected by hydration and testing conditions, consistency matters. Neither method directly measures strength, so results should be interpreted alongside physical performance, symptoms and nutritional history.

GLP-1 Care at HormoneSynergy®

HormoneSynergy® provides weight-management and GLP-1 treatment within concierge longevity care after the Optimal Aging Assessment. Weight loss is no longer offered as a separate stand-alone program. This pathway allows Dr. Kathryn Retzler to consider metabolic health, cardiovascular risk, body composition and other relevant findings before recommending treatment.

The assessment includes advanced laboratory testing, carotid artery ultrasound, SECA body-composition analysis, DEXA bone density and whole-body composition testing, neurocognitive testing and a comprehensive physician visit. Ongoing concierge care provides the setting for implementing the plan, monitoring response and adjusting treatment as needs change.

When semaglutide or tirzepatide is appropriate, care includes review of appetite, gastrointestinal tolerance, food intake, body-composition trends and relevant clinical findings. Medication decisions are made alongside nutrition and exercise planning. The Weight Loss for Longevity resource explains the broader clinical approach.

Planning for Maintenance

Obesity and weight-related metabolic disease often require ongoing management. Decisions about continuing, changing or stopping medication should account for the original indication, response, adverse effects, nutritional status and the likelihood of weight regain. A maintenance plan should be discussed during treatment rather than deferred until the desired weight is reached.

For older adults especially, success should include the ability to eat adequately, remain strong and continue ordinary activities. A treatment plan may need adjustment when weight falls faster than intended, intake becomes persistently inadequate or physical function deteriorates. Regular follow-up makes those changes easier to recognize and address.

Related HormoneSynergy® Resources

• Optimal Aging Assessment
• The HormoneSynergy® Longevity Medicine Model
• Weight Loss for Longevity Within Concierge Care
• DEXA Bone Density and Body-Composition Testing
• SECA Body-Composition Testing
• Longevity Medicine Resource Library

Frequently Asked Questions

Are GLP-1 medications only for weight loss?

No. Depending on the product and indication, these medications are used for type 2 diabetes, obesity and certain related complications. Treatment should follow the individual’s medical circumstances and the evidence for the specific medication.

Does weight loss with GLP-1 medications include muscle loss?

Body-composition studies show that weight loss can include lean tissue as well as fat. Lean tissue is not identical to skeletal muscle, so measurements should be considered alongside strength, function, nutrition and activity.

How much protein should I eat during treatment?

Targets of approximately 1.2–1.6 grams per kilogram per day have been proposed during weight reduction, but the appropriate amount and weight basis should be individualized. Kidney function, activity, body composition and overall nutritional status can change the recommendation.

Is protein enough to preserve muscle?

Adequate protein supports muscle preservation, but resistance training provides an important additional stimulus. A plan should address both nutrition and exercise, with follow-up when strength or physical function declines.

Can I enroll in a stand-alone GLP-1 program at HormoneSynergy®?

No. HormoneSynergy® provides GLP-1 and weight-management care within concierge longevity medicine following the Optimal Aging Assessment.

Selected References

• Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory. 2025.
• Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. 2025.
• Wilding JPH, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP-1 study. 2021.

This article provides educational information and does not replace individualized medical evaluation or treatment.